Cetirizine
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
Cetirizine: From Allergic Rhinitis to Allergic Urticaria
One-Sentence Summary
Cetirizine is a second-generation H1 antihistamine, originally used for allergic rhinitis, conjunctivitis and idiopathic urticaria. The TxGNN model predicts it may be effective for allergic urticaria, with 1 clinical trial (a completed Phase 3 pilot study of IV cetirizine) and 18 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Allergic rhinitis (also vasomotor rhinitis, pharyngitis, common cold, atopic/papillary/vernal conjunctivitis, nasopharyngitis, idiopathic urticaria) |
| Predicted New Indication | Allergic urticaria |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L1 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 20 |
| Recommended Decision | Proceed with Guardrails |
Note: The Singapore licence records do not include approved indication text. The original indications above come from the knowledge graph used by the model.
Why is This Prediction Reasonable?
Cetirizine is a selective peripheral H1-receptor antagonist. Detailed mechanism-of-action data was not available in the data compiled for this report, but this class effect is well established. In allergic urticaria, histamine released from mast cells drives the wheal-and-flare reaction, and blocking H1 receptors addresses this pathway directly.
Cetirizine is already associated with idiopathic urticaria. The predicted indication is therefore a close extension of an existing use, such as a label expansion or a new route or population (for example, an IV formulation), rather than a new mechanism. The retrieved literature also describes an IV cetirizine product approved in 2019 for acute urticaria in the US.
The evidence-level rating of L1 rests mainly on the Phase 3 label of the trial and the established efficacy of cetirizine in urticaria. The only trial is a small feasibility study, so a definitive efficacy RCT is not shown in the data.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02023164 | Phase 3 | Completed | 36 | Randomised, double-blind pilot study of IV cetirizine 10 mg vs IV diphenhydramine 50 mg in acute urticaria, run in emergency departments, urgent care centres and allergy clinics. It assessed the feasibility of a larger Phase 3 trial. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 34862952 | 2022 | Narrative review | Advances in Therapy | Role of IV cetirizine among IV antihistamines, approved in 2019 for acute urticaria |
| 40910677 | 2025 | Literature review | J Infus Nurs | IV cetirizine vs IV diphenhydramine as premedication; IV cetirizine is approved for acute urticaria and angioedema |
| 16278258 | 2005 | Review | Ann Pharmacother | Efficacy and safety of first- and newer-generation antihistamines in allergic rhinitis and chronic idiopathic urticaria |
| 7510611 | 1993 | Review | Drugs | Cetirizine is effective and well tolerated in seasonal/perennial allergic rhinitis and chronic idiopathic urticaria |
| 1981354 | 1990 | Review | Drugs | Pharmacology and clinical potential of cetirizine in allergic rhinitis, pollen-induced asthma and chronic urticaria |
| 1677011 | 1991 | Review | J Am Acad Dermatol | Low-sedating H1 antihistamines are the agents of choice for urticaria and angioedema |
| 7530629 | 1994 | Review | Drugs | Nonsedating antihistamines are the mainstay of treatment for chronic idiopathic urticaria |
| 17017922 | 2006 | Review | Curr Med Chem | Levocetirizine (the R-enantiomer of cetirizine) update |
| 12113226 | 2002 | Review | Clin Allergy Immunol | H1-antihistamines in children; Level 1 evidence in allergic rhinoconjunctivitis |
| 11034010 | 2000 | Case report | J Clin Gastroenterol | Case of cetirizine-induced cholestasis (safety signal) |
Singapore Market Information
Twenty valid single-ingredient registrations were identified. The main ones are listed below. Approved indication text was not available in the records.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN03022P | ZYRTEC TABLET 10 mg | Film-coated tablet | Not stated in records |
| SIN14890P | ZYRTEC-R FILM-COATED TABLET 10 MG | Film-coated tablet | Not stated in records |
| SIN10796P | ZYRTEC ORAL SOLUTION 1 mg/ml | Solution | Not stated in records |
| SIN08945P | ZYRTEC ORAL DROPS 10 mg/ml | Solution | Not stated in records |
| SIN15437P | ZYRTEC-R ORAL SOLUTION 1 MG/ML | Solution | Not stated in records |
Safety Considerations
- Contraindications (knowledge graph, not label text): The model's knowledge graph links cetirizine to the following conditions: hypertension, kidney disease (including chronic and end-stage renal failure), liver disease, gallbladder disease, diabetes mellitus and diabetic ketoacidosis, benign prostatic hyperplasia, coronary artery disease and atherosclerosis, angle-closure glaucoma, and hyperthyroidism (including Graves disease). These should be checked against the package insert.
- Drug Interactions: 100 interactions were recorded. The main moderate-level ones involve CNS-depressant or sedating agents and opioids: bupropion, dronabinol, nabilone, loperamide, metoclopramide, morphine (including liposomal), opium, sibutramine, difenoxin and diphenoxylate.
- Literature safety signals: A case of cetirizine-induced cholestasis was reported (PMID 11034010). Hypersensitivity reactions to antihistamines, including urticaria and angioedema, have also been described (PMID 24169055).
Please refer to the package insert for full safety information.
Other Predicted Indications (Brief)
| Predicted Indication | Score | Evidence Level | Suggested Decision |
|---|---|---|---|
| Cold urticaria | 99.95% | L3 | Proceed with Guardrails |
| Nasal cavity disease | 99.77% | L4 | Research Question |
| Angioedema | 95.72% | L4 | Research Question |
| Acute laryngopharyngitis, rosacea conjunctivitis, recalcitrant atopic dermatitis, atopic IgE responsiveness, punctate epithelial keratoconjunctivitis, trigeminal autonomic cephalalgia | 93.97–99.72% | L5 | Hold |
Cold urticaria has the most supporting evidence among the secondary candidates. One small study shows cetirizine reduced the cold-induced wheal by about 50% (PMID 17225008), and a small comparative study in primary acquired cold urticaria also included cetirizine (PMID 1364168).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanism is a direct and well-understood fit, since H1 blockade addresses histamine-driven urticaria, and cetirizine is already marketed in Singapore with 20 registrations. The only trial is a small Phase 3 pilot feasibility study (n=36), so efficacy for this specific indication still relies largely on existing use and review literature.
To proceed, the following is needed:
- HSA package insert warnings and contraindications (currently unavailable, and a blocking gap for safety screening)
- Detailed mechanism-of-action data from DrugBank
- Confirmation of the approved indication wording on the Singapore licences
- A definitive efficacy trial, or results of the full Phase 3 study, if an IV or new-population extension is pursued
- A review of the knowledge-graph contraindications (renal, hepatic, cardiovascular, glaucoma, prostatic) against label dosing guidance
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.